Phase III Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine for Tourette Syndrome and Attention Deficit Hyperactivity Disorder

This study has been completed.

First Received: October 18, 1999 Last Updated: June 23, 2005 History of Changes

Sponsors and Collaborators:	National Center for Research Resources (NCRR) Yale University
Information provided by:	Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:	NCT00004376

Purpose

OBJECTIVES:

I. Evaluate the safety and efficacy of the alpha-2 adrenergic agonist guanfacine in children and adolescents with Tourette syndrome or other chronic tic disorder, and attention deficit hyperactivity disorder.

Condition	Intervention	Phase
Tourette Syndrome	Drug: guanfacine	Phase III

Genetics Home Reference related topics: familial paroxysmal nonkinesigenic dyskinesia Tourette syndrome

MedlinePlus related topics: Attention Deficit Hyperactivity Disorder Tourette Syndrome

Drug Information available for: Guanfacine Guanfacine hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment:	35
Study Start Date:	September 1994
Estimated Study Completion Date:	June 2000

Detailed Description:

PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are stratified by pubertal status.

There is a 7- to 14-day washout with a placebo prior to treatment for all patients.

The first group receives oral guanfacine 3 times a day for 8 weeks. The dose is gradually increased to minimize sedation; by day 14, most patients are stabilized and the dose is then increased as clinically indicated and tolerated.

The second group receives a placebo 3 times a day for 8 weeks. Patients in either group may be treated with guanfacine for an additional 8 weeks.

Eligibility

Ages Eligible for Study:	7 Years to 16 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Tourette syndrome or other chronic tic disorder meeting Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria
DSM-IV diagnosis of attention deficit hyperactivity disorder (ADHD) Clinician's Global Impression for ADHD greater than 4 Hyperactivity Index of Conners Parent or Teacher Questionnaire standard score 65 or higher (1.5 standard deviation units)

--Prior/Concurrent Therapy--

At least 2 weeks since medication for tics, ADHD, or obsessive compulsive disorder (4 weeks since neuroleptics or fluoxetine)
No failure on prior guanfacine

--Patient Characteristics--

Hepatic: No liver failure
Renal: No renal failure
Cardiovascular: No hypertension No other heart disease
Pulmonary: No pulmonary disease
Other: No Intelligence Quotient below 80 No current DSM-IV diagnosis of the following: Major depression Bipolar disorder Pervasive developmental disorder Psychotic disorder No seizure disorder No other significant medical condition No pregnant women

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004376

Sponsors and Collaborators

National Center for Research Resources (NCRR)

Yale University

Investigators

Study Chair:

Lawrence Scahill

Yale University

More Information

No publications provided

Study ID Numbers:	199/11979, YALESM-7588
Study First Received:	October 18, 1999
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00004376 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):

Tourette syndrome
neurologic and psychiatric disorders
rare disease

Study placed in the following topic categories:

Neurotransmitter Agents
Adrenergic alpha-Agonists
Ganglion Cysts
Adrenergic Agents
Basal Ganglia Diseases
Rare Diseases
Attention Deficit and Disruptive Behavior Disorders
Central Nervous System Diseases
Tourette Syndrome
Cardiovascular Agents
Tic Disorders
Antihypertensive Agents

Neurodegenerative Diseases
Brain Diseases
Adrenergic Agonists
Tics
Heredodegenerative Disorders, Nervous System
Genetic Diseases, Inborn
Attention Deficit Disorder with Hyperactivity
Guanfacine
Mental Disorders
Movement Disorders
Mental Disorders Diagnosed in Childhood
Hyperkinesis

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Physiological Effects of Drugs
Basal Ganglia Diseases
Neurodegenerative Diseases
Brain Diseases
Adrenergic Agonists
Heredodegenerative Disorders, Nervous System
Pathologic Processes
Attention Deficit Disorder with Hyperactivity
Movement Disorders
Mental Disorders
Guanfacine

Syndrome
Therapeutic Uses
Mental Disorders Diagnosed in Childhood
Disease
Adrenergic alpha-Agonists
Nervous System Diseases
Central Nervous System Diseases
Attention Deficit and Disruptive Behavior Disorders
Tourette Syndrome
Tic Disorders
Cardiovascular Agents
Antihypertensive Agents
Pharmacologic Actions
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on May 07, 2009